Phase 1 trial of RE-024 to evaluate safety, tolerability, and pharmacokinetics in healthy adult subjects

Trial Profile

Phase 1 trial of RE-024 to evaluate safety, tolerability, and pharmacokinetics in healthy adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Fosmetpantotenate (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 20th International Congress of Parkinson's Disease and Movement Disorders.
    • 03 May 2016 According to Retrophin media release, results from this study were presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
    • 24 Mar 2016 According to a Retrophin media release, data from this trial will be presented at the 20th International Congress of Parkinsons Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top